Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To compare the antidepressant efficacy and safety of subjects receiving
DVS-233 SR versus subjects receiving placebo.
Secondary Objective: To assess the response of subjects receiving DVS-233 SR for the clinical
global evaluation, functionality, general wellbeing, pain, and absence of symptoms (Hamilton
Psychiatric Rating Scale for Depression, 17-item [HAM-D17] less than or equal to 7) versus
those subjects receiving placebo.